EATL
MCID: ENT008
MIFTS: 37

Enteropathy-Associated T-Cell Lymphoma (EATL)

Categories: Blood diseases, Cancer diseases, Gastrointestinal diseases, Immune diseases, Rare diseases

Aliases & Classifications for Enteropathy-Associated T-Cell Lymphoma

MalaCards integrated aliases for Enteropathy-Associated T-Cell Lymphoma:

Name: Enteropathy-Associated T-Cell Lymphoma 52 58 71
High-Grade Pleomorphic Peripheral T-Cell Lymphoma 52
Enteropathy-Type T-Cell Lymphoma 58
Intestinal T-Cell Lymphoma 58
Eatcl 52
Eatl 58
Ettl 58

Characteristics:

Orphanet epidemiological data:

58

Classifications:

Orphanet: 58  
Rare gastroenterological diseases
Rare haematological diseases


External Ids:

ICD10 32 C86.2
MESH via Orphanet 44 D058527
ICD10 via Orphanet 33 C86.2
UMLS via Orphanet 72 C0456889
Orphanet 58 ORPHA86880
UMLS 71 C0456889

Summaries for Enteropathy-Associated T-Cell Lymphoma

MalaCards based summary : Enteropathy-Associated T-Cell Lymphoma, also known as high-grade pleomorphic peripheral t-cell lymphoma, is related to celiac disease 1 and lymphoma. An important gene associated with Enteropathy-Associated T-Cell Lymphoma is SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase), and among its related pathways/superpathways are Akt Signaling and Reelin Pathway (Cajal-Retzius cells). The drugs Methotrexate and Pirarubicin have been mentioned in the context of this disorder. Affiliated tissues include t cells, small intestine and nk cells, and related phenotypes are hematopoietic system and immune system

Wikipedia : 74 Enteropathy-associated T-cell lymphoma (EATL), previously termed enteropathy-associated T-cell lymphoma,... more...

Related Diseases for Enteropathy-Associated T-Cell Lymphoma

Diseases related to Enteropathy-Associated T-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 113)
# Related Disease Score Top Affiliating Genes
1 celiac disease 1 11.0
2 lymphoma 11.0
3 peripheral t-cell lymphoma 10.7
4 refractory celiac disease 10.7
5 lymphoma, hodgkin, classic 10.6
6 lymphoma, non-hodgkin, familial 10.6
7 intestinal perforation 10.6
8 diarrhea 10.5
9 t-cell lymphoma, subcutaneous panniculitis-like 10.4
10 b-cell lymphoma 10.3
11 intestinal obstruction 10.3
12 gastrointestinal lymphoma 10.3
13 autoimmune disease 10.2
14 adult t-cell leukemia 10.2
15 inflammatory bowel disease 10.2
16 anaplastic large cell lymphoma 10.2
17 acute kidney failure 10.2
18 histiocytosis 10.2
19 infertility 10.2
20 t-cell leukemia 10.2
21 peptic ulcer disease 10.2
22 reticulosarcoma 10.2
23 ulcerative colitis 10.2
24 malignant histiocytosis 10.2
25 hypereosinophilic syndrome 10.2
26 autoimmune enteropathy 10.2
27 t-cell non-hodgkin lymphoma 10.2
28 severe immune-mediated enteropathy 10.2
29 peritonitis 10.2
30 marginal zone b-cell lymphoma 10.1
31 nodal marginal zone lymphoma 10.1
32 protein-losing enteropathy 10.1
33 hypothyroidism 10.1
34 splenomegaly 10.1
35 b-cell non-hodgkin lymphoma 10.1
36 lymphoproliferative syndrome 10.1
37 t-cell adult acute lymphocytic leukemia 10.1
38 hepatosplenic t-cell lymphoma 10.1
39 atrial standstill 1 10.1
40 burkitt lymphoma 10.1
41 intussusception 10.1
42 osteoporosis 10.1
43 anemia, autoimmune hemolytic 10.1
44 hypereosinophilic syndrome, idiopathic 10.1
45 neutrophilic dermatosis, acute febrile 10.1
46 myocardial infarction 10.1
47 bone mineral density quantitative trait locus 8 10.1
48 bone mineral density quantitative trait locus 15 10.1
49 cholangitis, primary sclerosing 10.1
50 deficiency anemia 10.1

Graphical network of the top 20 diseases related to Enteropathy-Associated T-Cell Lymphoma:



Diseases related to Enteropathy-Associated T-Cell Lymphoma

Symptoms & Phenotypes for Enteropathy-Associated T-Cell Lymphoma

MGI Mouse Phenotypes related to Enteropathy-Associated T-Cell Lymphoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.26 CCL11 CD3G ITGAE SETD2
2 immune system MP:0005387 8.92 CCL11 CD3G ITGAE SETD2

Drugs & Therapeutics for Enteropathy-Associated T-Cell Lymphoma

Drugs for Enteropathy-Associated T-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 99)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methotrexate Approved Phase 4 59-05-2, 1959-05-2 126941
2
Pirarubicin Investigational Phase 4 72496-41-4
3 Dermatologic Agents Phase 4
4
Melphalan Approved Phase 2 148-82-3 4053 460612
5
Epirubicin Approved Phase 2 56420-45-2 41867
6
Cytarabine Approved, Experimental, Investigational Phase 2 147-94-4, 65-46-3 6253
7
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
8
Carmustine Approved, Investigational Phase 2 154-93-8 2578
9
leucovorin Approved Phase 1, Phase 2 58-05-9 6006 143
10
Ifosfamide Approved Phase 2 3778-73-2 3690
11
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4
12
Daunorubicin Approved Phase 2 20830-81-3 30323
13
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
14
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
15
Etoposide Approved Phase 1, Phase 2 33419-42-0 36462
16
Cyclophosphamide Approved, Investigational Phase 2 6055-19-2, 50-18-0 2907
17
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
18
Vincristine Approved, Investigational Phase 2 57-22-7, 2068-78-2 5978
19
Prednisone Approved, Vet_approved Phase 1, Phase 2 53-03-2 5865
20
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
21
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
22
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
23 Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
24
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
25
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
26
Gemcitabine Approved Phase 2 95058-81-4 60750
27
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
28
Bortezomib Approved, Investigational Phase 2 179324-69-7 93860 387447
29
nivolumab Approved Phase 2 946414-94-4
30
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
31
Folic acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 59-30-3 6037
32
tipifarnib Investigational Phase 2 192185-72-1 159324
33
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
34
Cortisone Experimental Phase 1, Phase 2 53-06-5 222786
35
Emodepside Investigational, Vet_approved Phase 1, Phase 2 155030-63-0
36 Immunosuppressive Agents Phase 1, Phase 2
37 Proteasome Inhibitors Phase 2
38 Tin Fluorides Phase 2
39 Antibodies, Monoclonal Phase 2
40 Immunoglobulins Phase 2
41 Antibodies Phase 2
42 Anti-Bacterial Agents Phase 2
43 Folic Acid Antagonists Phase 1, Phase 2
44 Vitamin B Complex Phase 1, Phase 2
45 Vitamin B9 Phase 1, Phase 2
46 Antibiotics, Antitubercular Phase 2
47 Folate Phase 1, Phase 2
48
Isophosphamide mustard Phase 2 0
49 10-deazaaminopterin Phase 1, Phase 2
50 BB 1101 Phase 2

Interventional clinical trials:

(show all 30)
# Name Status NCT ID Phase Drugs
1 An Open-label,Multicenter Randomised Study of CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for the New Diagnosed Young Patients With T Cell Non-hodgkin Lymphoma Unknown status NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
2 Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients Unknown status NCT03023358 Phase 3 chidamide;cyclophosphamide;liposomal doxorubicin;vincristine;prednisone
3 CELTIC-1 (Clinical Evaluation of T-cell NHL With Cerdulatinib): A Phase 2b, Open Label, Multidose, Multinational Study of Cerdulatinib (PRT062070) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Not yet recruiting NCT04021082 Phase 2, Phase 3 Cerdulatinib
4 A Phase II Evaluation of High Dose Chemotherapy and Autologous Stem Cell Transplantation for Intestinal T-cell Lymphomas Unknown status NCT00669812 Phase 2 carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;melphalan;methotrexate;prednisolone;vincristine sulfate
5 Chimeric Antigen Receptor-Modified pNK Cells for CD7 Positive Relapsed or Refractory Leukemia and Lymphoma Unknown status NCT02742727 Phase 1, Phase 2
6 An Open Label Phase II Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma Unknown status NCT02464228 Phase 2 Tipifarnib
7 An Open-label Phase 2 Study of Intravenous Bortezomib and Oral Panobinostat (LBH589) in Adult Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma After Failure of Conventional Chemotherapy Completed NCT00901147 Phase 2 panobinostat and bortezomib
8 A Phase II Study of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin Lymphoma Completed NCT01336933 Phase 2 prednisone;cyclophosphamide;etoposide;Vincristine;pralatrexate
9 A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma Completed NCT00322985 Phase 2 Lenalidomide
10 A Phase I/II of Vorinostat Plus CHOP in Untreated T-cell Non-Hodgkin's Lymphoma Completed NCT00787527 Phase 1, Phase 2 Zolinza (vorinostat);Cyclophosphamide;Doxorubicin;Vincristine;Prednisone
11 Phase 2 Study of Brentuximab Vedotin Associated With CHP Followed by Consolidation With High-dose Therapy / Autologous Stem-cell Transplantation as Frontline Treatment of Patients With Enteropathy-associated T-cell Lymphoma Type 1. Recruiting NCT03217643 Phase 2 Brentuximab Vedotin
12 A Phase 1/2 Study of Pembrolizumab Plus Pralatrexate for Treatment of Relapsed or Refractory Peripheral T-Cell Lymphomas Recruiting NCT03598998 Phase 1, Phase 2 Pralatrexate
13 A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) Recruiting NCT02588651 Phase 2 Brentuximab vedotin
14 A Phase 2 Study of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients With CD30-Positive Peripheral T-Cell Lymphomas Recruiting NCT03113500 Phase 2 Brentuximab Vedotin;Cyclophosphamide;Doxorubicin;Doxorubicin Hydrochloride;Etoposide;Etoposide Phosphate;Prednisone
15 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With Peripheral T-cell Lymphoma (PTCL) Recruiting NCT02533700 Phase 2 CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles
16 CHEMO-T: Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (CHOP) Versus Gemcitabine, Cisplatin and Methyl Prednisolone (GEM-P) in the First Line Treatment Of T-cell Lymphoma,a Multicentre Randomised Phase II Study Active, not recruiting NCT01719835 Phase 2 Cyclophosphamide;Gemcitabine;Doxorubicin;Vincristine;Prednisolone;methylprednisolone;Cisplatin
17 A Phase I/II Trial of CHOEP Chemotherapy Plus Lenalidomide as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin's Lymphoma Active, not recruiting NCT02561273 Phase 1, Phase 2 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Lenalidomide;Prednisone;Vincristine Sulfate
18 Phase 2 Single-Arm, Open-Label Study of Nivolumab in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) Terminated NCT03075553 Phase 2
19 A Phase II Study To Determine The Safety and Efficacy Of The Combination of Vorinostat and Bortezomib In Patients With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma Terminated NCT00810576 Phase 2 Vorinostat;Bortezomib
20 Phase I Study of Romidepsin (ISTODAX®) Plus ICE for Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma Completed NCT01590732 Phase 1 Carboplatin;Etoposide;Ifosfamide;Romidepsin
21 An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Hematological Malignancies Completed NCT00697346 Phase 1 Alisertib
22 Phase I Study of the Humanized Mik-Beta-1 Monoclonal Antibody Directed Toward IL-2/IL-15R Beta (CD122) That Blocks IL-15 Action In Patients With Refractory Celiac Disease Recruiting NCT01893775 Phase 1
23 T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas Active, not recruiting NCT03049449 Phase 1 Cyclophosphamide;Fludarabine
24 A Phase 1 Trial of the Combination of Everolimus (RAD001) and Bortezomib (VELCADE) for Relapsed or Refractory Lymphoma Terminated NCT00671112 Phase 1 Bortezomib;Everolimus
25 Prospective Randomized Comparison Between Axial- and Lateral-viewing Capsule Endoscopy Systems in Celiac Patients: a Pilot Study Unknown status NCT03095573
26 A Pilot Feasibility Trial of the Tolerability of Oral Salvia Hispanica and Its Effect on Blood Fatty Acids and Stool Microbiome in Patients With Treated Non-Hodgkin Lymphoma Completed NCT02652715
27 Effect of Vitamin D Replacement on Tumor Response and Survival Parameters for Vitamin D Insufficient Patients With Cancer Recruiting NCT01787409
28 Assessing the Impact of Mobile Phone Technology to Improve Health Nutrition and Population (HNP) Service Utilization in Rural Bangladesh Through Pilot Intervention Recruiting NCT03189004
29 MRI Assessment in Newly Diagnosed Coeliac Disease and Following Gluten-free Diet Treatment Active, not recruiting NCT02551289
30 AMG 714 Expanded Access Program Available NCT03439475

Search NIH Clinical Center for Enteropathy-Associated T-Cell Lymphoma

Genetic Tests for Enteropathy-Associated T-Cell Lymphoma

Anatomical Context for Enteropathy-Associated T-Cell Lymphoma

MalaCards organs/tissues related to Enteropathy-Associated T-Cell Lymphoma:

40
T Cells, Small Intestine, Nk Cells, Colon, B Cells, Lymph Node, Bone Marrow

Publications for Enteropathy-Associated T-Cell Lymphoma

Articles related to Enteropathy-Associated T-Cell Lymphoma:

(show top 50) (show all 480)
# Title Authors PMID Year
1
Characterization of the fecal microbiome in cats with inflammatory bowel disease or alimentary small cell lymphoma. 61
31844119 2019
2
Monomorphic Epitheliotropic Intestinal T cell Lymphoma: a Rare Cause of Chronic Diarrhea. 61
30761475 2019
3
Multicenter retrospective analysis of the clinicopathologic features of monomorphic epitheliotropic intestinal T-cell lymphoma. 61
31493002 2019
4
Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas. 61
31709579 2019
5
T- and NK-cell lymphoproliferative disorders of the gastrointestinal tract: review and update. 61
31727264 2019
6
Anaplastic Large T-Cell Lymphoma in the Intestine of Dogs. 61
31170900 2019
7
Update on lymphoproliferative disorders of the gastrointestinal tract: disease spectrum from indolent lymphoproliferations to aggressive lymphomas. 61
31773249 2019
8
Bone marrow involvement by monomorphic epitheliotropic intestinal T-cell lymphoma. 61
31240703 2019
9
[Current standard in diagnostic and therapy of peripheral T-cell lymphoma]. 61
31594013 2019
10
A case of celiac disease with type I enteropathy-associated T-cell lymphoma in a Japanese male patient. 61
31603739 2019
11
An Unusual Case of Enteropathy-associated T-cell Lymphoma Type 2 with Pulmonary Metastasis. 61
31720182 2019
12
Two cases of monomorphic epitheliotropic intestinal T-cell lymphoma associated with coeliac disease. 61
31361171 2019
13
Gastrointestinal T- and NK-cell lymphomas and indolent lymphoproliferative disorders. 61
31522873 2019
14
[Mesenteric lymph node cavitation in celiac disease: Report of four cases and literature review]. 61
31155369 2019
15
Epidemiological, pathological and immunohistochemical aspects of 125 cases of feline lymphoma in Southern Brazil. 61
31461200 2019
16
DIFFERENTIATING ENTEROPATHY-ASSOCIATED T-CELL LYMPHOMA TYPE 2 FROM INFLAMMATORY BOWEL DISEASE IN A SNOW LEOPARD (UNCIA UNCIA). 61
31260218 2019
17
Successful treatment of monomorphic epitheliotropic intestinal T cell lymphoma with pralatrexate. 61
30173289 2019
18
Diffuse large B-cell lymphoma of the small intestine in a patient with refractory coeliac disease. 61
31025641 2019
19
Monomorphic epitheliotropic intestinal T cell lymphoma presenting in weblike feature. 61
30576648 2019
20
Management of celiac disease in daily clinical practice. 61
30528262 2019
21
Gastrointestinal: Endoscopic findings of monomorphic epitheliotropic intestinal T-cell lymphoma. 61
30225983 2019
22
Monomorphic epitheliotropic intestinal T-cell lymphoma with T-cell receptor (TCR) of silent phenotype shows rearrangement of TCRβ or TCRγ gene. 61
30576040 2019
23
BRAF V600E-positive monomorphic epitheliotropic intestinal T-cell lymphoma complicating the course of hairy cell leukemia. 61
31354304 2019
24
Immunohistochemical Profiling of Canine Intestinal T-Cell Lymphomas. 61
30278836 2019
25
[Enteropathy-associated T-cell lymphoma coexisting with composite lymphoma composed of DLBCL and PTCL]. 61
31068515 2019
26
Clinical and immunophenotypic findings in 4 forms of equine lymphoma. 61
30651648 2019
27
Monomorphic epitheliotropic intestinal T-cell lymphoma may mimic intestinal inflammatory disorders. 61
30757928 2019
28
Rare T-Cell Subtypes. 61
30596220 2019
29
Hypocalcemia Revealing an Enteropathy-Associated T-cell Lymphoma. 61
30858951 2019
30
[Acute intestinal intussusception revealing intestinal T-cell lymphoma in adults]. 61
31558950 2019
31
A Single-Tube, EuroClonality-Inspired, TRG Clonality Multiplex PCR Aids Management of Patients with Enteropathic Diseases, including from Formaldehyde-Fixed, Paraffin-Embedded Tissues. 61
30268943 2019
32
Truth lies below: A case report and literature review of typical appearing polyps yet with an atypical diagnosis. 61
30705732 2019
33
Risks for lymphoma and gastrointestinal carcinoma in patients with newly diagnosed adult-onset celiac disease: Consequences for follow-up: Celiac disease, lymphoma and GI carcinoma. 61
30574319 2018
34
Granulysin, a novel marker for extranodal NK/T cell lymphoma, nasal type. 61
30151671 2018
35
Primary cutaneous peripheral T-cell lymphoma with a late relapse solely in the ileum mimicking monomorphic epitheliotropic intestinal T-cell lymphoma. 61
30477646 2018
36
Intestinal T-cell and NK/T-cell lymphomas: A clinicopathological study of 27 Chinese patients. 61
30317149 2018
37
Pathological features of intestinal T-cell lymphoma in Shiba dogs in Japan. 61
29575510 2018
38
Recurrent monomorphic epitheliotropic intestinal T-cell lymphoma with aberrant CD20 expression: An implication for anti-CD20 (rituximab) antibody therapy? 61
30402988 2018
39
Update on Gastrointestinal Lymphomas. 61
30407861 2018
40
TP53 mutations in peripheral mature T and NK cell lymphomas: a whole-exome sequencing study with correlation to p53 expression. 61
29885407 2018
41
Peripheral T-Cell Lymphomas: Incorporating New Developments in Diagnostics, Prognostication, and Treatment Into Clinical Practice-PART 2: ENKTL, EATL, Indolent T-Cell LDP of the GI Tract, ATLL, and Hepatosplenic T-Cell Lymphoma. 61
30153323 2018
42
A locus at 7p14.3 predisposes to refractory celiac disease progression from celiac disease. 61
29787419 2018
43
Pathogenesis of Enteropathy-Associated T Cell Lymphoma. 61
29943210 2018
44
Peripheral T-Cell Lymphomas: Incorporating New Developments in Diagnostics, Prognostication, and Treatment Into Clinical Practice-PART 1: PTCL-NOS, FTCL, AITL, ALCL. 61
30080923 2018
45
Colonal monomorphic epitheliotropic intestinal T-cell lymphoma with novel phenotype of cytoplasmic CD3 expression. 61
29657256 2018
46
Type II enteropathy-associated t-cell lymphoma: A case report and literature review. 61
29888733 2018
47
CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial. 61
29703335 2018
48
Novel findings from the Asian Lymphoma Study Group: focus on T and NK-cell lymphomas. 61
29380182 2018
49
Expression of activating natural killer-cell receptors is a hallmark of the innate-like T-cell neoplasm in peripheral T-cell lymphomas. 61
29363227 2018
50
Intestinal T-cell lymphoma with enteropathy-associated T-cell lymphoma-like features arising in the setting of adult autoimmune enteropathy. 61
29446107 2018

Variations for Enteropathy-Associated T-Cell Lymphoma

Expression for Enteropathy-Associated T-Cell Lymphoma

Search GEO for disease gene expression data for Enteropathy-Associated T-Cell Lymphoma.

Pathways for Enteropathy-Associated T-Cell Lymphoma

Pathways related to Enteropathy-Associated T-Cell Lymphoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.28 ITGAE CD3G CCL11
2 10.63 ITGAE CD3G

GO Terms for Enteropathy-Associated T-Cell Lymphoma

Cellular components related to Enteropathy-Associated T-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.62 ITGAE CD3G

Sources for Enteropathy-Associated T-Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....